Washington University Pancreatic Cancer Program
Washington University SPORE in Pancreatic Cancer
New immune-focused and metabolism-targeting treatments for people with pancreatic ductal adenocarcinoma (PDAC).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11187256 on NIH RePORTER |
What this research studies
As a patient with pancreatic cancer, I would be part of a program at Washington University and partner sites testing immune-based and metabolic therapies specifically for PDAC. The program links three research projects that lead to investigator-initiated therapeutic trials, and it uses a biospecimen core to collect patient samples plus a biostatistics and bioinformatics core to analyze results. It also supports early-stage (developmental) studies and career development to bring promising ideas to clinical testing faster. Clinical care, genomics, and immune monitoring are used to personalize treatments and track responses.
Who could benefit from this research
Good fit: People diagnosed with pancreatic ductal adenocarcinoma who meet clinical trial eligibility at Washington University or participating centers would be ideal candidates.
Not a fit: People without PDAC, those too frail or with medical conditions that exclude trial enrollment, or those who do not meet safety criteria may not benefit directly.
Why it matters
Potential benefit: If successful, this work could produce new immune-based or metabolism-directed treatments that extend survival or improve quality of life for people with PDAC.
How similar studies have performed: Immune therapies for pancreatic cancer have been challenging, so these trials build on emerging and largely experimental approaches rather than on widely proven treatments.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Denardo, David G — Washington University
- Study coordinator: Denardo, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.